Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Overview of attention for article published in Allergy, Asthma & Clinical Immunology, January 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news: 1 news outlet
twitter: 2 X users

googleplus: 2 Google+ users

Readers on

mendeley: 12 Mendeley

Summary News X Google+

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 3,070 followers.

RT @Allergy_bio: Dermatomyositis associated with omalizumab therapy for severe asthma: a #casereport: Omalizumab is a humanized monoclonal…

20 Jan 2019

Reply Repost Favourite

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report https://t.co/cbfQasBVFs https://t.co/36lYODuRSM

18 Jan 2019

Reply Repost Favourite

Dermatomyositis associated with omalizumab therapy for severe asthma: a #casereport: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse… ht

18 Jan 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.